drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Off-the-shelf allogeneic CAR T cells employing a 4SCAR construct specific for CD19 to eliminate CD19-expressing B-lineage cells, potentially addressing myeloma subpopulations and normal B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Off-the-shelf allogeneic T cells are engineered to express a 4SCAR chimeric antigen receptor targeting CD19. Upon binding CD19 on B-lineage cells and relevant myeloma subpopulations, CAR signaling (CD3zeta with co-stimulation) activates the T cells to release cytotoxic molecules and cytokines, leading to selective killing and depletion of CD19-expressing malignant and normal B cells.
drug_name
Universal allogeneic anti-CD19 4SCAR T cells
nct_id_drug_ref
NCT06006741